RANOZEX HAS ANTIANGINAL AND ANTI-ISCHEMIC EFFECTS THAT DO NOT DEPEND UPON REDUCTIONS IN HEART RATE OR BLOOD PRESSURE. THE MECHANISM OF ACTION OF RANOLAZINE IS UNKNOWN. IT DOES NOT INCREASE THE RATE-PRESSURE PRODUCT, A MEASURE OF MYOCARDIAL WORK, AT MAXIMAL EXERCISE. BECAUSE RANOZEX PROLONGS THE QT INTERVAL, IT SHOULD BE RESERVED FOR PATIENTS WHO HAVE NOT ACHIEVED AN ADEQUATE RESPONSE WITH OTHER ANTIANGINAL DRUGS. RANOZEX SHOULD BE USED IN COMBINATION WITH AMLODIPINE, BETA-BLOCKERS OR NITRATES. RANOZEX IS ONLY FOR PATIENTS NOT RESPONDING ADEQUATELY TO OTHER ANTIANGINAL DRUGS